Clinical utility of 18 F ‐fluorodopa positron emission tomography in the movement disorder clinic: an Australian experience
Internal Medicine Journal · 2025
DOI: 10.1111/imj.16615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Dennis Yeow und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Dihydroxyphenylalanine, Movement Disorders, Parkinson Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Differentiating idiopathic Parkinson disease (iPD) from other causes of tremor and parkinsonism based on clinical grounds can be challenging, particularly early in the course of disease or in the case of atypical clinical presentations. 18 F‐fluorodopa (F‐DOPA) is a positron emission tomography (PET) radioligand that can be used to demonstrate the presence and pattern of striatal presynaptic dopaminergic deficit and, thus, assist in the diagnosis of iPD and related disorders.
Aims
To determine the clinical utility of F‐DOPA PET in an Australian movement disorder clinic setting.
Methods
Retrospective cohort study of movement disorder clinic patients referred for F‐DOPA PET by four movement disorder neurologists over a 10‐year period to a single Australian nuclear medicine centre. Results of F‐DOPA PET scans were correlated with changes in provisional diagnosis and management in the short term following review of F‐DOPA PET results.
Results
A total of 105 F‐DOPA PET scan results and patient records were examined. In this cohort, provisional clinical diagnosis was altered in 37.9% of patients, and changes to clinical management were made in 48.4% of patients in the short term following review of F‐DOPA PET results. Changes in both diagnosis and management were more common following a normal F‐DOPA PET scan result (42.4% and 53.0% respectively) than a scan consistent with iPD (23.5% and 32.4% respectively).
Conclusions
There was significant change in provisional clinical diagnosis and management in the short term following review of F‐DOPA PET results indicating significant clinical utility of F‐DOPA PET in the Australian movement disorder clinic setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia.
- Department of Nuclear Medicine, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia.
- Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia.
- Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
- Department of Medicine, Redcliffe Hospital, Brisbane, Queensland, Australia.
- Department of Neurology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
ORCID-Profile: Dennis Yeow
Zitieren
APA
Yeow, D., Fielder, M., Hynard, S., Adam, R., Katz, M., Lehn, A., Thomas, P., & O'Sullivan, J. D. (2025). Clinical utility of 18 F ‐fluorodopa positron emission tomography in the movement disorder clinic: an Australian experience. Internal Medicine Journal. https://doi.org/10.1111/imj.16615
Vancouver
Yeow D, Fielder M, Hynard S, Adam R, Katz M, Lehn A, et al. Clinical utility of 18 F ‐fluorodopa positron emission tomography in the movement disorder clinic: an Australian experience. Internal Medicine Journal. 2025. doi:10.1111/imj.16615
BibTeX
@article{Yeow2025,
author = {Yeow, Dennis and Fielder, Matthew and Hynard, Shane and Adam, Robert and Katz, Matthew and Lehn, Alexander and Thomas, Paul and O'Sullivan, John D},
title = {Clinical utility of 18 F ‐fluorodopa positron emission tomography in the movement disorder clinic: an Australian experience},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.16615}
}
EUVIMED